Infection or inflammation may precede and trigger the formation of microvascular thrombosis in patients with acquired thrombotic thrombocytopenic purpura (TTP).
Key Points

HNPs inhibit proteolytic cleavage of von Willebrand factor (VWF) by ADAMTS13 by
physically blocking VWF-ADAMTS13 interactions.
2. Plasma levels of HNP1, HNP2, and HNP3 are markedly increased in patients with acquired autoimmune TTP.
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Introduction
Thrombotic thrombocytopenic purpura (TTP), characterized by disseminated plateletrich microvascular thrombosis, is primarily caused by severe deficiency of plasma metalloprotease ADAMTS13 activity 1 . Inherited mutations of ADAMTS13 and de novo production of autoantibodies against ADAMTS13 result in severe deficiency of plasma ADAMTS13 activity in hereditary 1, 2 and acquired (idiopathic) TTP 1, 3 , respectively. The age of onset in patients with hereditary TTP directly correlates with plasma ADAMTS13 activity; the lower plasma ADAMTS13 activity, the earlier the clinical onset 4 . Similarly, low levels of plasma ADAMTS13 activity in the presence of inhibitors but not the anti-ADAMTS13 immunoglobulin G (IgG) levels themselves are associated with the high incidence relapse and mortality rates in patients with acquired TTP 5, 6 . These results suggest that ADAMTS13 inhibitors may not be restricted to anti-ADAMTS13 IgG antibodies. For instance, ADAMTS13-specific immunoglobulin A (IgA) or immunoglobulin M (IgM) antibodies were detected in a small subset of patients with acquired TTP 5 ; the affinity of anti-ADAMTS13 antibodies for their epitopes and the frequency of the targeted epitopes may vary from one patient to another; in addition, free hemoglobin 7, 8 and unconjugated bilirubin 9 may inhibit plasma ADAMTS13 activity.
However, the mechanisms that regulate plasma ADAMTS13 activity under normal and pathological conditions are not fully understood.
It is often noted that respiratory, gastrointestinal, and central line infections precede an acute episode of TTP [10] [11] [12] , suggesting a potential link between infection/inflammation and microvascular thrombosis, the hallmark of pathological changes in TTP. During acute infections or systemic inflammation, human neutrophil peptides (HNPs), most
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From abundantly HNP1, HNP2, and HNP3 (also known as α-defensins), are released from activated neutrophils 13 . These cationic and hydrophobic ~29-30 amino acid polypeptides contribute to the innate immune response by binding and forming pores within the membranes of bacteria, viruses, and fungi leading to microbial death 13 .
Plasma concentrations of HNPs in healthy individuals are in the nanomolar range (or on average, ∼0.12 μg/ml), but the levels increase to the 100 μM range in patients with sepsis, bacterial meningitis 14 , and systemic lupus erythematosus 15 .
In addition to their role in innate immunity, HNPs affect host cells in proximity to the sites of inflammation. HNPs activate platelets by enhancing the interactions between platelets and fibrinogen or thrombospondin-1 leading to aggregation, secretion of granule contents, shedding of soluble CD-40L, and the expression of platelet surface procoagulant activity 16 . In addition, HNPs may inhibit fibrinolysis by modulating the binding of tissue plasminogen activator (t-PA) and plasminogen to fibrin and endothelial cells 17 . The resultant localized microvascular thrombosis may be an integral component in host defense, but might also lead to infection/inflammation-associated microvascular thrombosis in settings where plasma ADAMTS13 levels are extremely low as in the cases of TTP.
Here, we demonstrate for the first time that HNPs inhibit the proteolytic cleavage of peptidyl VWF73 and multimeric VWF by ADAMTS13 in a concentration-dependent manner. This inhibitory effect appears to be mediated by tight binding between HNPs and VWF-A2 domain, which presumably competes for binding of ADAMTS13 to VWF and renders it resistant to proteolysis. Plasma levels of HNPs1-3 or HNP1, HNP2, and was defined in adult patients by the presence of marked thrombocytopenia (usually <50,000/μl), microangiopathic hemolytic anemia, organ dysfunction, severe deficiency of plasma ADAMTS13 activity (<10% of normal) with detectable inhibitors and a negative direct antiglobulin test. Patients with overt sepsis, disseminated intravascular coagulation, pregnancy, cancer, and hematopoietic progenitor cell transplantation at the presentation were excluded from the study. Healthy controls (n=18) were recruited from regular blood donors. After informed consent was obtained, 5 ml of whole blood was collected by peripheral venous puncture (healthy donors) at time of blood donation or via central catheter (TTP patients) prior to the initiation of the first therapeutic plasma exchange. The blood was anti-coagulated with 0.32% sodium citrate (final concentration) and platelet poor plasma was prepared by centrifugation at 1,500xg for 10 min and stored in aliquots at -80 °C until assay.
Human neutrophil peptides (HNPs) were purified to homogeneity from sputum collected from patients with cystic fibrosis using methods described previously 18, 19 .
Synthetic peptides of wild type (WT) HNP1
(ACYCRIPACIAGERRYGTCIYQGRLWAFCC) and two analogs: HNP1-RRY/AAA (ACYCRIPACIAGEAAAGTCIYQGRLWAFCC) and HNP1-delRRY (ACYCRIPACIAGE---GTCIYQGRLWAFCC) were chemically synthesized at Peptide 2.0 (Chantilly, VA). The For personal use only. on October 28, 2017. by guest www.bloodjournal.org From RRY motif that is homologous to that found in the spacer domain of ADAMTS13 is underlined.
Recombinant human ADAMTS13 (rADAMTS13) was expressed and purified to homogeneity from the conditioned medium of stably transfected human embryonic kidney (HEK)-293 cells as described [20] [21] [22] . Multimeric human VWF was purified from cryoprecipitate of normal human plasma using ion exchange and gel filtration chromatography as described 
ADAMTS13 activity assays
Proteolytic activity of rADAMTS13 in the absence or in the presence of purified or synthetic HNPs (0-150 μM) was determined by the cleavage of rF-VWF73 24, 25 and multimeric VWF 27,28 under denaturing conditions using 1.5 M urea as previously described.
Surface plasmon resonance
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The binding kinetics of HNPs to GST-VWF73-H and multimeric VWF was measured by surface plasmon resonance technology using the BIAcore3000 optical biosensor instrument (Biacore AB, Uppsala, Sweden) as described 22 . Briefly, a CM5-sensor chip (Biacore AB) was activated and immobilized with nothing (blank), with purified plasma VWF or with recombinant GST-VWF73-H. Unbound amine groups were blocked with 1 mol/L ethanolamine at pH 8. 
Binding of HNPs to soluble VWF multimers
Purified HNPs (0.2~2.0 µg) were incubated with plasma VWF (10 µg) in a total volume of 50 µl in the presence of 20 mM HEPES, 150 mM NaCl, pH 7.4 for 30 min. The reaction was terminated by addition of 1x SDS-sample buffer (0.5 M Tris-HCl, pH 6.8, 5% SDS, 10% glycerol, 0.5% bromophonol blue) without heat denaturation. Binding of HNPs to purified VWF was measured using monoclonal anti-HNP1-3 (1:1,000) (Hycult Biotech Inc., Plymouth Meeting, PA), followed by alexaFluor488-conjugated anti-mouse IgG (1:5,000) (Thermo Fisher Scientific) after electrophoresis on 1% SDS-agarose gel.
To visualize VWF multimers, the same blot was subsequently incubated with rabbit antihuman VWF IgG (1:2,000) (Dako, Carpinteria, CA), followed by AlexaFluor594-conjugated anti-rabbit IgG (Thermo Fisher Scientific) (1:5,000). The fluorescent signals were obtained by scanning in an Odyssey CLx infrared imaging system (LI-COR, Lincoln, NE).
Binding of HNPs to Ultra large VWF on cultured endothelial cells under flow
Human umbilical vein endothelial cells (HUVEC) were grown to near confluence on a flow chamber slide (Ibidi-Integrated BioDiagnostics, Germany) coated with gelatin. The cells were washed and 100 μM histamine was added under flow (10 dyne/cm 2 ) for 5 min. Alexa488-labeled HNPs (10 µg/ml) were perfused through the channel for an additional 20 min. Alexa488-labeled non-immune IgG (green) was used as a control.
After the cells were washed with PBS, they were fixed with 4% paraformaldehyde and permeabilized with 1% Triton X-100. The VWF "strings" along the endothelial surface were visualized under a Nikon fluorescent microscope after incubation with Alexa594-labeled anti-VWF IgG (10 µg/ml) (red).
Enzyme-linked immunoassay
Total plasma levels of HNPs1-3 were determined by an enzyme-linked immunoassay (ELISA) according to manufacturer's recommendation (Hycult Biotech Inc., Plymouth Meeting, PA). Briefly, standards (at various dilutions) or plasma samples (1:100-1:2,000) were added to a microtiter plate pre-coated with a monoclonal anti-human antibody that recognizes HNPs1-3. The reaction mixtures were incubated at 25 ºC for 60 min. After three washes, a biotinylated monoclonal antibody that recognizes HNPs1-3 at a different epitope was added to the wells and incubated at 25 ºC for 60 min, 
Statistical analysis
All statistical analysis was performed using GraphPad Prizm6 software (La Jolla, CA).
The results are expressed as scatter plots showing the medians and ranges as indicated in the table and in each figure. Statistical significance was determined using non-parametric Mann-Whitney test for comparison between two groups (unpaired and two-tailed) and Spearman's rank correlation coefficient (rho) for comparison between ELISA and LC-MS/MS. P values less than 0.05 and 0.01 were considered to be statistically significant and highly significant, respectively.
RESULTS
HNPs inhibit proteolytic cleavage of rF-VWF73 and multimeric VWF by ADAMTS13
To investigate the effect of HNPs on VWF proteolysis by ADAMTS13, we first purified native HNPs, plasma VWF, and rADAMTS13 as described in the Methods. The rADAMTS13 protein migrated as a single band at the molecular weight of ∼195 kDa on a 15% SDS-polyacrylamide gel (Fig. 1A, lane 1 When purified HNPs were added to reactions containing either purified rADAMTS13 (10 nM) and rF-VWF73 (2 μM) or multimeric VWF (25 μg/ml), proteolytic cleavage of both rF-VWF73 ( Fig. 2A ) and multimeric VWF (Fig. 2B ) was inhibited in a concentrationdependent manner, with half-maximal inhibitory concentrations (IC 50 ) of ∼3.5 μM and ∼45 μM, respectively. As a positive control, ethylene diamine tetra acetic acid (EDTA) (10 mM) added to the same reaction caused complete inhibition of rADAMTS13 mediated cleavage of VWF (Fig. 2B, lane 7) . Moreover, HNPs added to plasma or whole blood also inhibited its ADAMTS13 activity, assessed by the cleavage of rF-
VWF73, in a concentration-dependent manner (not shown). These results indicate that
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HNP1, HNP2, and HNP3, the most abundant peptides released from neutrophils following activation, are nearly identical in sequence except for the first amino acid residue with alanine and aspartic acid in HNP1 and HNP3, respectively, which is lacking in HNP2 (Fig. 3A) . HNP4, which is not detected in the granular contents of neutrophils, consists of 34 amino acid residues with similar disulfide bond patterning, but differing in sequence from HNP1, HNP2, and HNP3. HNP1-3 share a RRY motif, which is also present in the spacer domain of ADAMTS13 (Fig. 3A) and may play an important role in substrate recognition, presumably by interacting with the C-terminal end of VWF73 as illustrated in the model (Fig. 3B & 3C) . We hypothesized that the RRY motif in HNP1-3 might interact directly with amino acid residues E1660 and D1663 in the VWF73 peptide ( Fig.3D & 3E) . To test this hypothesis, we prepared three synthetic HNP1 peptides (i.e.
wild-type HNP1, HNP1-RRY/AAA, and HNP1-delRRY). When added to the reactions containing rADAMTS13 (10 nM) and rF-VWF73 (2 μM) under the same conditions, wild type HNP1, HNP2 (not shown), and HNP3 (not shown) inhibited proteolytic cleavage of rF-VWF73 (Fig. 3F ) and multimeric VWF (Fig. 3H ) in a concentration-dependent manner. However, mutant HNP1-RRY/AAA or HNP1-delRRY) did not inhibit rADAMTS13-mediated proteolysis of rF-VWF73 (Fig. 3F ) and multimeric VWF (Fig. 3G) .
As an additional control, synthetic β-defensin, a small cationic/hydrophobic, highly disulfide linked peptide, which lacks the RRY motif, did not inhibit proteolytic cleavage of rF-VWF73 by rADAMTS13 (Fig. 3F) . Together, our results indicate that a specific (Fig. 4D) . Together, these results demonstrate that HNPs bind VWF and with autoimmune TTP and 18 healthy controls by ELISA and LC-MS/MS assays. Fifteen patient samples (∼80%) were collected at the time of their initial presentation and the remainder were collected upon relapse. The median platelet counts of these patients were 15,000/μl (range 6,000-40,000/μl) and all except two had plasma ADAMTS13 activity of less than 5% (ranging from <5% to 8%) ( Table 1) . A commercial ELISA was used to measure total plasma levels of HNPs1-3, whereas LC-MS/MS was used to detect HNP1, HNP2, and HNP3 separately based on the m/z ratio and the peptide fragmentation after the most abundant proteins were removed by acid precipitation. As shown in Table 1 and Figure 5 , the median plasma levels of HNPs1-3 in TTP patients during the acute episodes were ∼170 ng/ml (58 to 3,570 ng/ml, n=19), significantly higher than those in healthy controls ∼23 ng/ml (6 to 44 ng/ml, n=18) ( Table 1 & Fig.   5A ). The difference between HNP levels in the two groups was statistically highly significant (p<0.0001). The median plasma levels of HNP1, HNP2, and HNP3 were 8.4 AU/ml (Fig. 5B), 6 .0 AU/ml (Fig. 5C) , and 3.1 AU/ml (Fig. 5D) , respectively, in the same TTP patients, ∼6-11 fold higher that those in the healthy controls (∼1 AU/ml) ( Table 1 ).
There was a good correlation between ELISA and LC-MS/MS for measuring HNPs1-3 (Fig. 3) . These three residues RRY are also present in the spacer domain of ADAMTS13 that is known to interact with the terminal nine amino acid residues in the VWF73 peptide, which is essential for ADAMTS13-mediated proteolysis of the peptidyl substrate 34 . Based on modeling, we hypothesize that the RRY residues in HNPs1-3 may interact directly with E1660 and D1663 residues in the VWF73 peptide and VWF (Fig. 3) , physically blocking the binding of the spacer domain (RRY) of ADAMTS13 to the substrates, and thereby inhibiting proteolysis of VWF by ADAMTS13 under the assay conditions described.
HNPs have the ability to dimerize, oligomerize, and multimerize on targeted surfaces of bacterial, viral, and host origin 13 . An impaired ability of HNP1 to dimerize correlates with its reduced antibacterial activity against S. aureus, inhibition of anthrax lethal factor and impaired binding to HIV-1 gp120
35
. However, it remains to be determined whether this propensity of HNPs to oligomerize contributes to its inhibitory potency on ADAMTS13-dependent proteolysis of VWF. The much lower K D assessed by the binding assay (Fig. 4 ) than the IC 50 in the functional assays (Fig. 2) Several limitations of our studies should be noted. Activation of complement 43, 44 , cytokines and other inflammatory pathways 45 may also contribute to the development of thrombosis in TTP, as suggested by the variation in plasma HNPs1-3 levels in 
Acknowledgement
The work is supported in part by a grant from Answering T.T.P. Foundation, R01HL115187-01A1 and R01HL126724-01 to X.L.Z., R56-HL123912 to D.B.C. and R21NS091793-01 to K.B. comparing with that in the mean value of each HNP in normal human plasma (defined as having 1 Arbitrary Unit, AU)/ml). F demonstrates the Spearman's rank correction coefficient (rho=0.7932) between LC-MS/MS and ELISA for measurement of total plasma levels of HNP1-3 using GraphPad Prizm6. P values less than 0.05 and 0.01 are considered to be statistically significant and highly significant. Abbreviation: TTP, thrombotic thrombocytopenic purpura; HNP, human neutrophil peptide; LC-MS/MS, liquid chromatography and tandem mass spectrometry; ELISA, enzyme-linked immunosorbent assay; AU, arbitrary units; All patients received plasma exchange therapy. All samples were collected prior to the first therapeutic plasma exchange.
Conflicts of Interest
